|
| Author | Study duration | Stage of trial | Sample size | Study design | Country of study | Mean age | Gender (male) | Efficacy measures | Adverse reactions | Sarilumab dose |
|
| Della-Torre et.al. | 14 March–2 April, 2020 | | 56 | Open-label observational study | Italy | 56 (51–60) | 44 | PaO2/FiO2 ratio
Mortality (six-point scale)
Others | Infections
Neutropenia
Increase of liver enzymes
Thromboembolism | Single IV 400 mg
Two single-dose 200 mg sarilumab IV over 1 hour |
| Montesarchio et.al. | March 26, 2020, to April 3, 2020 | | 15 | Retrospective | Italy | 59 (53–75) | 12 | PaO2/FiO2 ratio
Mortality
Others | Thrombocytopenia | Single IV 400 mg
Two doses (2nd) after 24 hours of the first |
| Benucci et.al. | 14 days | | 8 | Open-label, observational study | Italy | 62 | 6 | PaO2/FiO2 ratio
Others | NA | Single IV 400 mg
Two single-dose 200 mg sarilumab IV over 1 hour |
| Lescure et.al. | 60 days | Phase III | 420 | Randomised, double-blind, placebo-controlled study | Multinational | 59 (50–68) | 261 | PaO2/FiO2 ratio
Mortality (seven-point scale)
Others | Infection
Treatment-emergent adverse effect | Sarilumab 200 or 400 mg IV |
| Gremese et.al. | March 23rd till April 4, 2020 | | 53 | Open-label, observational study | Italy | 66 (40–95) | 47 | PaO2/FiO2 ratio
Mortality
Others | No notable adverse effects | 400 mg IV on day 1 and 2; sarilumab 200 mg IV |
|
